Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;82(4):1179-1187.e2.
doi: 10.1016/j.jvs.2025.05.047. Epub 2025 May 29.

Aneurysm sac regression after fenestrated or branched endovascular aortic repair is associated with superior long-term survival

Affiliations
Free article

Aneurysm sac regression after fenestrated or branched endovascular aortic repair is associated with superior long-term survival

Kiera Zehner et al. J Vasc Surg. 2025 Oct.
Free article

Abstract

Objective: Aneurysm sac behavior after fenestrated or branched endovascular repair (FB-EVAR) of thoracoabdominal aortic aneurysms (TAAAs) remains a key knowledge gap. The purpose of this study was to identify independent predictors of sac behavior after FB-EVAR and assess the relationship between sac behavior and long-term survival.

Methods: Patients undergoing FB-EVAR between 2005 and 2023, in 10 physician-sponsored investigational device exemption studies in the United States, were analyzed. Patients who underwent elective FB-EVAR for juxtarenal, suprarenal, or extent 1 to 5 TAAAs and had 30-day and 1-year computed tomography follow-up imaging were included. Patients with chronic aortic dissections were excluded. Sac regression or expansion (≥5 mm) was defined using the Society for Vascular Surgery guidelines. Independent predictors of sac growth were identified using multivariable logistic regression analysis and survival rates were compared using Kaplan-Meier curves.

Results: Of 3057 patients who underwent FB-EVAR, 1497 were eligible for analysis. Median follow-up was 2.9 years (interquartile range, 1.3-4.0 years). At 1 year, 103 (6.9%) patients experienced sac expansion, 694 (46.4%) experienced sac regression, and 700 (46.7%) had a stable sac. Variables independently associated with sac expansion were age (odds ratio [OR] 1.04; 95% confidence interval [CI], 1.01-1.07; P = .0057), prior aortic surgery (OR, 2.22; 95% CI, 1.32-3.40; P = .0026), prior EVAR (OR, 1.84; 95% CI, 1.07-3.14; P = .0264), larger aneurysm diameter (OR, 1.03; 95% CI, 1.01-1.04; P = .0014), type II endoleak observed on 30-day follow-up computed tomography (OR, 2.15; 95% CI, 1.36-3.41; P = .0011), and any secondary intervention during the first year (OR, 2.19; 95% CI, 1.35-3.55; P = .0016). Overall survival at 1 year was significantly lower in the expansion group compared with the stable and regression groups (85.6% vs 90.9% vs 93.1%, respectively). This effect persisted on 5-year evaluation (48.1% vs 63.0% vs 67.7%, respectively). Both expansion and stability at 1 year were both associated with increased long-term mortality in unadjusted cox model (expansion, hazard ratio, 2.083; 95% CI, 1.47-2.95; P < .0001; stability, hazard ratio, 1.26; 95% CI, 1.02-1.56; P = .0298) vs regression.

Conclusions: Both aneurysm sac expansion and stability (lack of regression) one year after FB-EVAR are associated with decreased long-term survival compared with sac regression. These outcomes underscore the need for vigilant monitoring of patients without sac regression and to better understand if interventions to address factors associated with unfavorable aneurysm sac behavior can improve long-term survival.

Keywords: Aortic aneurysm; Endovascular aneurysm repair; Fenestrated/branched EVAR; Mortality; Thoracoabdominal aortic aneurysm; Type II endoleak.

PubMed Disclaimer

Conflict of interest statement

Disclosures A.S. reports consulting fees that were paid to UMass Memorial Foundation for Artivion Inc, Phillips Healthcare, and Cook Medical Inc. A.B. reports consulting fees that were paid to UAB for Artivion Inc, Cook Medical Inc, Medtronic Inc, Philips Healthcare, and Terumo Aortic. G.O. has been paid a consulting fee by W. L. Gore & Associates, Inc., and GE Healthcare. G.O. consulted for Cook Medical Inc and Centerline Biomedical with no fees. C.T. has been paid a consulting fee by Centerline Biomedical, Cook Medical Inc, and W. L. Gore & Associates, Inc. W.G. has been paid a consulting fee by Cook Medical Inc, Philips Healthcare, and W.L. Gore & Associates, Inc. M.F. has been paid a consulting fee by Cook Medical Inc, Getinge, ViTTA, and W.L. Gore & Associates, Inc., and owns stock options in Centerline Biomedical. M.E. has been paid a consulting fee by Cook Medical Inc, Terumo Aortic, and W. L. Gore & Associates, Inc. D.S. has been paid a consulting fee by Abbott, Boston Scientific, Cook Medical Inc, Medtronic, Penumbra, Philips Healthcare, Silk Road Medical, and W. L. Gore & Associates, Inc.

MeSH terms

LinkOut - more resources